GTC Biotherapeutics (fka GTCB)

[DewDiligence]

> MAXY – I actually looked at them but thought it was a bit too early for me to speculate and to wait and see how their products advance.<

MAXY is early and no one yet knows if its claim of being able to make biosuperior drugs will pan out. What we do know is that MAXY’s business model is a lot riskier than GTC’s (#msg-15638633).

Clearly, MAXY is an interesting company—one that I might buy at some point.